InMed Pharmaceuticals Inc. (INM) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica.
InMed Pharmaceuticals Inc. Fundamental Analysis
Price to Book (PBV) Ratio
Undervalued price-to-book. INM stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER)
INM equity is higher than it's debt.
Small market capitalization. Market capitalization is less than 2bn USD
INM has never had growing revenue.
Net Income Growth
INM has never had growing net income.
INM never has positive net income for 2 years.
INM has low dividend yield (0%).
Return of Assets
INM has low return of asset (-131.23%).
Return of Equity
INM has low return of equity (-169.59%).
INM never has positive revenue for 2 years.
Return of Invested Capital
INM has low ROIC.
InMed Pharmaceuticals Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 1,089,435 USD
- 14,881,191 USD
- Net Income
- -18,600,117 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -15,622,866 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||-1.2x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||32.49%|
|Net Profit Margin (NPM)||-1357.14%|
|Return of Assets (ROA)||-131.23%|
|Return of Equity (ROE)||-169.59%|
|Return on Capital Employed (ROCE)||-127.22%|
|Days of Sales Outstanding (DSO)||3.93|
|Days of Inventory Outstanding (DIO)||478.13|
|Days Payable Outstanding (DPO)||294.7|
|Operating Cycle (OC)||479.1|
|Cash Conversion Cycle (CCC)||-172.88|
InMed Pharmaceuticals Inc. Executives
- CEO Name
- Mr. Eric A. Adams
InMed Pharmaceuticals Inc. Profile
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
- Company name
- InMed Pharmaceuticals Inc.
- NASDAQ Capital Market
815 West Hastings Street